Search

Search Constraints

You searched for: Author/Creator Inati, Adlette

Search Results

1. 13‐valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6‐17 years of age with sickle cell disease previously vaccinated with 23‐valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Issue 8 (23rd March 2015)

2. Establishment of a formal program for retinoblastoma: Feasibility of clinical coordination across borders and impact on outcome. Issue 11 (18th August 2019)

3. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Issue 8 (21st April 2022)

5. Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months. Issue 5 (25th February 2021)

6. Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry. (4th March 2021)

7. One‐year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Issue 1 (31st August 2016)

8. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Issue 5 (May 2021)

9. A double‐blind, placebo‐controlled phase II study of the efficacy and safety of 2, 2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell disease. Issue 7 (15th April 2014)

10. A dose‐escalation phase IIa study of 2, 2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell disease. Issue 11 (3rd October 2013)